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ABSTRACT 
MYH9 has been proposed as a major genetic risk locus for a 
spectrum of non-diabetic end stage kidney disease (ESKD). We use 
recently released sequences from the 1000 Genomes Project to 
identify two western African specific missense mutations (S342G and 
I384M) in the neighbouring APOL1 gene, and demonstrate that these 
are more strongly associated with ESKD than previously reported 
MYH9 variants. We also show that the distribution of these risk 
variants in African populations is consistent with the pattern of 
African ancestry ESKD risk previously attributed to the MYH9 gene. 
Additional associations were also found among other members of the 
APOL gene family, and we propose that ESKD risk is caused by 
western African variants in members of the APOL gene family, 
which evolved to confer protection against pathogens, such as 
Trypanosoma. 
 
 
 
 
 
 
 
 
 
 
  
INTRODUCTION 
Mapping by admixture linkage disequilibrium (MALD) localized an 
interval on chromosome 22, in a region that includes the MYH9 gene, 
which was shown to contain African ancestry risk variants associated 
with certain forms of ESKD (Kao et al. 2008; Kopp et al. 2008). This led 
to the new designation of MYH9 associated nephropathies (Bostrom and 
Freedman 2010). Subsequent studies identified clusters of single 
nucleotide polymorphisms (SNPs) within MYH9 with the largest odds 
ratios (OR) reported to date for the association of common variants with 
common disease risk (Bostrom and Freedman 2010; Nelson et al. 2010). 
These MYH9 association studies were then extended to earlier stage and 
related kidney disease phenotypes, and to population groups with varying 
degrees of recent African ancestry admixture (Behar et al. 2010; Nelson 
et al. 2010). However, despite intensive efforts including re-sequencing 
of the MYH9 gene, no suggested functional mutation has been identified 
(Nelson et al. 2010). This led us to re-examine the MALD interval 
surrounding MYH9, and to the detection of novel missense mutations 
with predicted functional effects in the neighbouring APOL1 gene, that 
are significantly more associated with ESKD than all previously reported 
SNPs in MYH9. Additional associations were found among other 
members of the APOL gene family, and we propose that variants in 
members of the APOL gene family, which evolved to confer protection 
against pathogens, currently account for increased kidney disease risk in 
African ancestry populations, and account for the MALD peak previously 
attributed to MYH9. 
 
 
 
 
 
 
 METHODS 
 
Sample sets 
The ESKD sample set is a sub-set of a larger ESKD cohort previously 
reported, excluding individuals designated diabetic nephropathy as the 
cause of ESKD (Behar et al. 2010). The designation of MYH9 associated 
nephropathies included hypertension affiliated chronic kidney disease, 
HIV-associated nephropathy (HIVAN), and non-monogenic forms of 
focal segmental glomerulosclerosis (Bostrom and Freedman 2010). The 
sample includes 430 non-diabetic ESKD cases and 525 controls, all of 
whom are self-identified as either African American or Hispanic 
American. We have already reported the African, European and Native 
American ancestry admixture proportions for these samples, based on a 
set of 40 genome wide Ancestry Informative Markers, and also the 
association and risk parameters for a set of 42 SNP polymorphic markers 
in the MYH9 genetic locus in the entire sample set (Behar et al. 2010).  
The African populations sample set consists of 676 samples from 12 
African populations, including Cameroon (2 ethnic groups), Congo, 
Ethiopia (4 ethnic groups), Ghana (2 groups), Malawi, Mozambique, 
Sudan with details provided in Table 1. Whole Genome Amplification of 
extracted DNA was carried out as previously reported (van Eijk et al. 
2010). 
All sampling and testing was conducted with institutional review board 
approval for human genetic studies on anonymized samples, with 
informed consent. 
 
 
 
 
 
 
 SNP Genotyping 
Genotyping of the novel six SNPs reported herein was performed with 
the KasPar methodology (Petkov et al. 2004). In addition we also 
designed PCR and RFLP reactions for the APOL1 SNPs as described in 
the legend to Figure 1. SNP validation was performed by Sanger 
sequencing. 
 
Statistical Analysis 
To search for variants possibly associated with ESKD, we examined a 
1.55 Mbp interval surrounding MYH9, spanning nucleotide positions 
34,000,000 to 35,550,000 (NCBI36 assembly) in 119 whole genome 
sequences recently released in the 1000Genomes Project 
(www.1000genomes.org). Of these, 60 are of European origin (HapMap 
CEU cohort), and 59 are of West-African origin (HapMap YRI cohort) 
yielding a total of 7,479 SNPs. We selected from these for further 
examination all SNPs which complied with the following conditions:  
1. Minor allele frequency in the CEU cohort not exceeding 7.5% 
(9/120 chromosomes). This minor allele was designated as a 
putative "risk state" for this SNP. 
2. Risk state in the YRI cohort at allele frequency exceeding 17.5% 
(21/118 chromosomes). 
3. A minimal level of LD with the MYH9 S-1 SNP rs5750250. The 
criterion used was a chi-square test p-value not exceeding 0.15 for 
the 3*3 genotype table comparing each candidate SNP to the S-1 
SNP in the YRI cohort. 
 All candidates which passed these requirements (total 250) were 
inspected in order to identify non-synonymous exonic SNPs, indicating a 
possible functional role. These non-synonymous SNPs were again 
examined for consistency with association patterns in the leading MYH9 
intronic risk variants S-1 (rs5750250) and F-1 (rs11912763) (Nelson et al. 
2010). The high attributable risk for S-1, especially for HIVAN (Winkler 
et al. 2010), indicates that the functional causative variant should be 
extremely rare in the presence of the protective state (G:G) for the S-1 
rs5750250 variant. This filtering process yielded the four candidate non-
synonymous exonic SNPs for genotyping, shown in Table 2a. 
 
Association analysis: For determining the association of each SNP with 
ESKD in our dataset, we performed logistic regression with ESKD status 
(Cases/Control) as the response, and included covariates for local and 
global ancestry as well as for cohort (African American/Hispanic 
American). Ancestry estimates were calculated as previously described 
(Behar et al. 2010). In addition to the four exonic SNPs described in 
Table 2a, we chose two additional SNPs in the APOL1 region for 
genotyping, namely SNP rs9622363 located in intron 3, and SNP 
rs60295735 located in the intergenic region between the genes APOL1 
and MYH9. These SNPs were chosen using the same statistical criteria 
described above which yielded the candidate exonic SNPs. 
We tested three major modes of association (recessive, additive, 
dominant) through definition of appropriate dummy variables in the 
regression. In addition to this combined analysis, we also performed the 
regression analysis in each cohort separately, and combined the resulting 
p-values using Fisher's meta-analysis. Results are shown in Table 1b. 
For determining whether the APOL1 SNP rs73885319 explains the 
association of ESKD with MYH9 SNPs, we performed a logistic 
regression with the same covariates, but included both APOL1 and 
MYH9 SNPs in the analysis. To avoid committing to a specific mode of 
inheritance, we included the SNPs as categorical variables with three 
values (three possible genotypes), and then performed an analysis of 
deviance on the results (Hastie and Pregibon 1992), first adding the 
APOL1 SNP, and then the MYH9 SNP, and performing a chi-square test 
for the null hypothesis that the MYH9 SNP does not add to our ability to 
explain ESKD status.  
Residual associations of MYH9 SNPs beyond LD with APOL1 missense 
mutations were performed using analysis of deviance tests (Hastie and 
Pregibon 1992) of the hypothesis that the APOL1 missense mutation 
rs73885319 can account for the statistical association between MYH9 
SNPs and ESKD status.  
 
RESULTS AND DICUSSION 
We analyzed 119 whole genome sequences recently released by the 1000 
Genomes Project (www.1000genomes.org). Of these, 60 are of European 
origin (CEU), and 59 are of West-African origin (YRI) yielding a total of 
7,479 SNPs in the 1.55 Mbp chromosome 22 interval surrounding MYH9 
and spanning nucleotide positions 34,000,000 to 35,550,000 (NCBI36). 
We applied the filtering criteria described in Methods to identify 
candidates SNPs for further consideration and analysis. Of the 250 
variants that met these criteria, which includes all of the six members of 
the human ApoL gene family, four are coding region non-synonymous 
mutations (Table 2a). The first two (rs73885319 and rs60910145) are 
missense mutations in the last exon of the APOL1 gene (S342G and 
I384M) which is the neighboring gene, located 14 kbp 3' downstream 
from MYH9. A third SNP (rs11089781) is a nonsense mutation (Q58X) 
in the APOL3 gene located 110 kbp further 3' downstream. The fourth 
SNP (rs56767103) is a missense mutation (R71C) in the gene FOXRED2 
located 100 kbp upstream to the 5' side of MYH9 (Figure 2). Of note the 
two variants located 128 bp apart in APOL1 are in almost perfect LD 
(237 out of 238 chromosomes from the 1000 Genomes Project).  
These four variants were genotyped in a previously reported sample set of 
African American and Hispanic American cases and controls (n=955) 
(Behar et al. 2010) and association analysis conducted as described in 
Methods. Table 2a shows the association results for the combined dataset 
of the African American and Hispanic American cohorts. For 
comparison, we include the results from the two previously reported 
leading MYH9 risk variants (S-1 rs5750250, F-1 rs11912763) (Nelson et 
al. 2010). The APOL1 missense variants (rs73885319 and rs60910145) 
are more strongly associated with ESKD risk than the leading MYH9 risk 
variants, both in terms of OR and p values. The lower allele frequency 
and OR, with a higher p value for the APOL3 nonsense variant, and the 
weak association for the FOXRED2 missense mutation, render these 
variants unlikely candidates to explain the risk attributed to this genomic 
region. We also show that the results for combined and meta-analysis of 
the two separate cohort-based results are congruent (Table 2b). 
Analysis of deviance of the combined logistic regression indicates that 
LD with APOL1 SNP rs73885319 accounted for much or all the 
statistical association previously attributed to the leading MYH9 variants 
with ESKD. In this regard, we also examined two non-coding variants in 
the APOL1 region which are in high LD with the APOL1 missense 
mutations, and as expected, both showed significant disease risk 
association (Figure 3 and Table 2b). Analysis of deviance also shows that 
the associations of the E-1 and F-1 haplotype SNPs are satisfactorily 
explained by this mutation (p>0.5 for F-1, p>0.1 for E-1). For the S-1 
SNP rs5750250, we obtain a borderline p-value of 0.01, indicating the 
possibility that the S-1 SNP may carry an association signal beyond its 
LD with rs73885319. We expect that this point will be further clarified 
once additional case control cohorts are examined. Another possibility, is 
that a one or more additional variants within the region, and in particular 
among the ApoL gene family members, which did not pass the statistical 
filter, is also causally related to ESKD risk, such that analysis of deviance 
based on a single causative variant would not account for all of the 
MYH9 risk association. 
 
HIVAN has been considered as the most prominent of the non-diabetic 
forms of kidney disease within what has been termed the MYH9-
associated nephropathies (Kopp et al. 2008). We have reported absence of 
HIVAN in HIV infected Ethiopians, and attributed this to host genomic 
factors (Behar et al. 2006). Therefore, we examined the allele frequencies 
of the APOL1 missense mutations in a sample set of 676 individuals from 
12 African populations, including 304 individuals from four Ethiopian 
populations (Table 1). We coupled this with the corresponding 
distributions for the African ancestry leading MYH9 S-1 and F-1 risk 
alleles. A pattern of reduced frequency of the APOL1 missense 
mutations, and also of the MYH9 risk variants was noted in northeastern 
African in contrast to most central, western and southern African 
populations examined (Figure 4a). Especially striking was the complete 
absence of the APOL1 missense mutations in Ethiopia. This combination 
of the reported lack of HIVAN and observed absence of the APOL1 
missense mutations is consistent with APOL1 being functionally relevant 
gene for HIVAN risk and likely the other forms of kidney disease 
previously associated with MYH9. 
The concomitant absence of the MYH9 F-1 risk variant in the Ethiopian 
samples examined, is consistent with the causative mutation in APOL1 
occurring on a phylogenetic branch in evolution of the region, following 
the appearance of the S-1 risk and prior to the occurence of the F-1 risk 
variants, previously reported for MYH9 (Figure 4b). Indeed, F-1 risk 
homozygotes in our dataset uniformly have the S-1 rs5750250 
homozygote risk state (data not shown). 
The APOL1 gene encodes apolipoprotein L-1, whose known activities 
include powerful trypanosomolysis (Lecordier et al. 2009). Trypanosoma 
brucei rhodesiense transmitted by tsetse flies prevalent in central and 
western Africa is a cause of human African trypanosomiasis, and shows 
resistance to this trypanosomolytic effect, by virtue of expressing serum 
resistance–associated protein (SRA), which interacts with the C-terminal 
domain of apolipoprotein L-1 (Lecordier et al. 2009). The S342G variant 
is predicted to modify the binding site of the C-terminal domain of the 
APOL1 gene product (Figure 5a/b/c). With respect to kidney disease risk, 
APOL1, and other APOL family members are also prominently involved 
in authophagic pathways (Zhaorigetu et al. 2008), and a recent study has 
provided compelling evidence for the role of well preserved authophagy 
in the integrity of renal glomerular podocytes (Hartleben et al. 2010). 
Moreover, apolipoproteins have also been identified as circulating 
inhibitors of glomerular proteinuria (Candiano et al. 2001). Functional 
assays of the effect of the APOL1 missense variants described herein in 
appropriate experimental model systems will be needed to link the strong 
and biologically plausible association to a functional pathogenic pathway 
in kidney disease, and to the possible selective factors which contributed 
to the observed African allele frequency distribution. 
Further studies of variants in other APOL family members are also 
warranted. The evolution of the APOL gene family in primates, is 
consistent with their role in protection from pathogens via mechanisms 
involving programmed cell death of the infected host cell, or alternatively 
direct pathogen killing as in the case of circulating APOL1 (reference to 
Smith and Malik). In particular, APOL2, whose kidney expression is 
restricted to the glomerular compartment, as opposed to APOL1 whose 
kidney expression is restricted to the tubule compartment (Human Protein 
Atlas Website link), is warranted. In particular Arg182Cys (rs7285167), 
which did not pass statistical filtering may still be considered for 
association and functional studies. Less is known about other non-
synonymous variants, such as (Ser155Arg , rs132653 in APOL3) While 
our current study strongly favors the missense variants Ser342Gly   
and Ile384Met in the last exon of the APOL1 gene as leading causative 
candidates, we also raise the possibility that more than one variant among 
the APOL gene family members may account for disease risk causation 
and for the MALD peak, which had originally focused attention on 
MYH9. 
The current findings strongly suggest that the intensive efforts 
(http://www3.niddk.nih.gov/fund/other/MYH9KidneyDisease/) currently 
underway to identify the ESKD disease phenotype risk causative variant 
in the chromosome 22 MALD peak should certainly be extended beyond 
the MYH9 locus. In particular, a strong emphasis should also be placed 
on the APOL1 missense mutations. 
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TABLES 
Table 1. The African populations sample set (total n=676), location, and risk 
allele frequencies for rs73885319 (S342G) in APOL1. 
Country Population 
Sample 
Size Latitude  Longitude  
rs73885319 
risk allele 
frequency 
Ghana Bulsa 22 10.7 -1.3 11% 
Ghana Asante 35 5.8 -2.8 41% 
Cameroon Somie 65 6.45 11.45 16% 
Congo COG 55 -4.25 15.28 11% 
Malawi MWI 50 -13.95 33.7 12% 
Mozambique Sena 51 -17.45 35 12% 
Sudan Kordofan 30 13.08 30.35 0% 
Cameroon Far-North-CMR/Chad 64 12.5 14.5 1% 
Ethiopia Afar 76 12 41.5 0% 
Ethiopia Amhara 76 11.5 38.5 0% 
Ethiopia Oromo 76 9 38.7 0% 
Ethiopia Maale 76 7.6 37.2 0% 
Note to Table 1: The samples analyzed in Table 1 form part of the collection of DNA 
maintained by The Centre for Genetic Anthropology at University College London. 
Buccal cells were collected with informed consent and institutional ethics approval 
from anonymous donors unrelated at the paternal grandfather level, classified by self 
declared ethnic identity.  
 
 
 
 
 
 
Table 2a. Association with non-diabetic ESKD of non-synonymous SNPs in APOL1, APOL3 and FOXRED2 in the MALD peak and 
comparison with leading MYH9 SNPs. 
rs number Gene Type 
Chr22 
Location
a
 Alleles
b
 
YRI risk 
frequency
c
 
CEU risk 
frequency Mode
d
 OR P value 
rs73885319
e
 APOL1 exon 5 34,991,852 A/G 46% 0% Recessive 6.7 2.71E-06 
    S342G missense        Additive 2.22 2.38E-08 
              Dominant 2.23 8.11E-06 
rs60910145 APOL1 exon 5 34,991,980 T/G 45% 0% Recessive 6.74 9.89E-06 
    I384M missense        Additive 2.28 3.00E-08 
              Dominant 2.32 4.75E-06 
rs11089781 APOL3 exon 1 34,886,714 G/A 31% 0% Recessive 6.62 2.82E-03 
    Q58X nonsense        Additive 2.18 3.79E-06 
              Dominant 2.22 3.23E-05 
rs56767103 FOXRED2 exon 1 35,232,205 G/A 18% 0% Recessive 1.33 6.83E-01 
    R71C missense        Additive 1.52 5.19E-02 
              Dominant 1.66 3.64E-02 
rs11912763 MYH9 intron 33 35,014,668 G/A 48% 0% Recessive 2.38 2.86E-02 
    F-1 designation        Additive 1.96 4.05E-05 
              Dominant 2.28 4.20E-05 
rs5750250 MYH9 intron13 35,038,429 A/G 66% 6% Recessive 2.48 4.29E-05 
    S-1 designation        Additive 1.78 6.68E-05 
              Dominant 1.55 4.97E-02 
a Location on Chromosome 22 in NCBI36 assembly. 
b African ESKD "risk" state in bold. 
c Frequencies according to available 1000genome data. 
d Association results were derived using logistic regression, correcting for global and local African ancestry, and combining the Hispanic and 
African American cohorts. 
e See Figure 6 for allele frequency pie-charts in cases versus controls. 
 
Table 2b. Association of the examined SNPs in the MALD peak with non-diabetic ESKD in African and Hispanic Americans. 
               Hispanic American African American  
Combined 
analysis 
rs number 
Chr22 
Location 
Gene Type 
Allel
es 
YRI 
risk 
freq. 
CEU 
risk 
freq. 
Mode OR lower upper p-value OR lower upper p-value 
Meta-
analysis 
p-value 
OR p-value 
rs73885319 34991852 APOL1 exon 5 A/G 0.457 0 Recessive 15.48 3.99 60.00 8.8E-04 4.86 2.35 10.06 3.5E-04 4.9E-06 6.70 2.7E-06 
     S342G missense      Additive 3.59 2.21 5.83 1.5E-05 1.90 1.46 2.48 5.9E-05 2.0E-08 2.22 2.4E-08 
              Dominant 3.47 1.95 6.16 3.7E-04 1.89 1.34 2.67 2.2E-03 1.2E-05 2.23 8.1E-06 
rs60910145 34991980 APOL1 exon 5 T/G 0.449 0 Recessive 12.80 3.28 49.94 2.1E-03 5.05 2.29 11.13 7.4E-04 2.2E-05 6.74 9.9E-06 
     I384M missense      Additive 3.54 2.17 5.78 2.3E-05 1.94 1.48 2.56 7.3E-05 3.5E-08 2.28 3.0E-08 
              Dominant 3.56 2.00 6.33 3.0E-04 1.95 1.37 2.76 1.8E-03 8.1E-06 2.32 4.8E-06 
rs60295735 34997100 Intergenic Intergenic G/A 0.432 0 Recessive 12.79 3.28 49.92 2.1E-03 2.99 1.56 5.73 5.8E-03 1.5E-04 4.27 1.2E-04 
     (APOL1-MYH9)      Additive 3.43 2.10 5.60 3.6E-05 1.76 1.35 2.31 5.6E-04 3.8E-07 2.10 4.6E-07 
              Dominant 3.32 1.87 5.91 5.9E-04 1.87 1.31 2.66 3.5E-03 2.9E-05 2.22 1.5E-05 
rs9622363 34986501 APOL1 intronic A/G 0.711 0 Recessive 5.11 2.36 11.06 5.2E-04 3.68 2.46 5.52 1.2E-07 1.5E-09 3.92 6.3E-10 
           Additive 2.80 1.73 4.53 4.2E-04 2.34 1.79 3.06 1.8E-07 1.8E-09 2.46 2.6E-10 
              Dominant 2.03 1.15 3.60 4.1E-02 2.26 1.41 3.61 4.3E-03 1.7E-03 2.20 3.2E-04 
rs56767103 35232205 FOXRED2 exon 1 G/A 0.177 0 Recessive Inf 0.00 Inf 9.9E-01 1.02 0.33 3.17 9.8E-01 1.0E+00 1.33 6.8E-01 
     R71C missense      Additive 2.75 1.40 5.41 1.4E-02 1.23 0.84 1.82 3.7E-01 3.3E-02 1.52 5.2E-02 
              Dominant 2.69 1.33 5.46 2.1E-02 1.33 0.85 2.10 3.0E-01 3.9E-02 1.66 3.6E-02 
rs11089781 34886714 APOL3 exon 1 G/A 0.305 0 Recessive 2.30 0.42 12.44 4.2E-01 13.06 2.43 70.14 1.2E-02 3.1E-02 6.62 2.8E-03 
     Q58X nonsense      Additive 2.57 1.55 4.24 2.0E-03 2.01 1.45 2.78 4.2E-04 1.3E-05 2.18 3.8E-06 
              Dominant 2.87 1.66 4.96 1.5E-03 1.93 1.32 2.82 4.3E-03 8.2E-05 2.22 3.2E-05 
rs4821480 35025193 MYH9 intron23 T/G 0.763 0.058 Recessive 3.37 1.56 7.29 9.6E-03 1.82 1.24 2.69 1.1E-02 1.1E-03 2.05 6.6E-04 
     E-1 designation      Additive 1.67 1.06 2.63 6.4E-02 1.64 1.23 2.19 4.4E-03 2.6E-03 1.65 6.5E-04 
              Dominant 1.14 0.66 1.99 6.9E-01 1.92 1.10 3.36 5.6E-02 1.6E-01 1.47 1.0E-01 
rs5750250 35038429 MYH9 intron13 A/G 0.661 0.058 Recessive 3.82 1.67 8.73 7.5E-03 2.29 1.54 3.43 6.7E-04 6.7E-05 2.48 4.3E-05 
     S-1 designation      Additive 1.50 0.96 2.34 1.4E-01 1.92 1.45 2.54 1.3E-04 2.1E-04 1.78 6.7E-05 
              Dominant 1.02 0.60 1.74 9.5E-01 2.28 1.37 3.81 7.8E-03 4.4E-02 1.55 5.0E-02 
rs11912763 35014668 MYH9 intron 33 G/A 0.483 0 Recessive 4.31 1.21 15.34 5.9E-02 1.95 0.95 3.99 1.3E-01 4.4E-02 2.38 2.9E-02 
     F-1 designation      Additive 3.02 1.80 5.08 4.7E-04 1.67 1.23 2.27 5.8E-03 3.8E-05 1.96 4.1E-05 
              Dominant 3.64 1.97 6.75 5.7E-04 1.90 1.29 2.79 6.2E-03 4.8E-05 2.28 4.2E-05 
 
 
Note to Table 2b: Table 2b includes in addition to the SNPs in Table 2a, also similarly derived results on several previously described associated 
SNPs in the MYH9 gene. The Table also demonstrates similarity between the p values obtained from combining the p values from the separate 
cohort based analyses (African American, Hispanic American) in a meta analysis, and the p values obtained directly from a combined analysis of 
both cohorts including an indicator for cohort. This demonstrates the robustness of the statistical conclusions to variations in methodology. 
 
 
 
 
FIGURES 
Figure 1. RFLP reaction for APOL1 missense mutations. 
 
 
 
SNP RS73885319 A/G: The allele containing G eliminates APOL1 SNP rs73885319 
(alleles A/G) eliminated a recognition site of endonuclease Hind III. SNP 
RS60910145 T/G: The allele containing TAPOL1 SNP rs60910145 (alleles T/G) 
generates a new recognition site of endonuclease NspI. Thus to confirm and screen for 
the mutations, we amplified by PCR a 538 bp fragment that contains both these SNPs. 
For PCR amplification we used the forward primer: 5’- ACA AGC CCA AGC CCA 
CGA CC-3’ and the reverse primer: 5’- CCT GGC CCC TGC CAG GCA TA-3’. 
PCR reaction mix included 30ng template DNA with 7.5 pmol of each primer and we 
used the Red Load Taq Master (Larova). PCR conditions were 95°c for 3 minutes 
followed by 40 cycles at 95°c for 30 seconds, 65°c for 20 seconds, 72°c for 1 minute ; 
the resulting amplicon was digested with both endonucleases Hind III and NspI. The 
resulting amplicon was digested separately with endonucleases Hind III and NspI, and 
run on a 2% agarose gel. 
 
 
 
 
 
 
Figure 2. Schematic view of the chromosomal region encompassing the examined SNPs. 
 
 
 
 
 
 
 
Figure 3. LD plot of the ESKD associated SNPs in the APOL1 and MYH9 
region. 
 
 
Linkage disequilibrium (LD) plot of non-diabetic ESKD associated SNPs in APOL1 
and MYH9 genes with their physical locations on chromosome 22. The color scheme 
represents the pairwise linkage disequilibrium value (D'/LOD) for the 4 new SNPs 
outside MYH9 (2 of which are missense mutations in APOL1) and for the previously 
published 01 MYH9 SNPs described in (Behar et al. 2010). The LD plot was 
calculated based on the African American control samples (n = 140). The plot was 
generated using the program HaploView (Barrett et al. 2005). Bright red squares 
presents SNPs with linkage LOD ≥ 2 and D'=1.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4a. Spatial allele frequency distributions in Africa of the ESKD risk variants. 
 
 
The given contour maps correspond to: a) MYH9 S-1 SNP rs5750250); b) MYH9 F-1 SNP (rs11912763); c) APOL1 S342G missense mutation 
(rs73885319). Maps were generated based on genotyping 12 African populations (n=676) (Table 1), using Surfer V.9 (Golden Software). 
Populations locations are marked (red circles for Ethiopia). Risk allele frequencies in Ethiopia and in South-Ghana are indicated. Notably, the most 
strongly associated MYH9 S-1 rs5750250 risk variant retains a 35% allele frequency in Ethiopians, while the Ethiopian allele frequencies for 
MYH9 F-1 rs11912763 and APOL1 missense mutation rs73885319 are zero. This pattern is consistent with the occurrence of the APOL1 missense 
mutations on a phylogenetic branch of the genomic region following the appearance of the MYH9 S-1 risk variants but prior to the appearance of 
the MYH9 F-1 risk variant. Indeed, F-1 risk homozygotes in our dataset uniformly have the S-1 rs5750250 homozygote risk state (data not shown).
  
Figure 4b. A phylogenetic tree of the MYH9 and APOL1 phased haplotypes. 
 
 
 
 
Note: this tree was created by the program PHASE, based on 28 SNPs across the 
genes MYH9 and APOL1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The S-1 major branch 
The F-1 and APOL1missense 
sub-branch 
  
Figures 5 (a,b and c). Predicted peptide structures of the C-terminus domain of 
the APOL1 gene product (amino acid positions 339-398) that contains the 
missense mutations S342G and I384M. All predictions were generated using the 
program I-TASSER (Zhang 2008, 2009), structures were edited with the program 
CHIMERA (Pettersen et al. 2004). All suggested predicted structures had Tm value 
>0.5. 
 
a)  Predicted structure and location of amino acid changes. C-terminus domain is 
predicted to have a bent alpha-helix structure. The mutation I384M is located 
on the external surface of the predicted alpha-helix, while the S342G is buried 
inside. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
b) Hydrophobicity of the predicted peptide surface (RED- hydrophobic amino-
acids, BLUE- polar amino-acids). Hydrophobic core is predicted to stabilize 
the bent C-terminus helical structure. 
 
 
c) Identified binding site in the predicted structure of the APOL1 C-terminus 
domain (Zhang 2008, 2009), based on similarity to an analogous known 
binding site (Billas et al. 2003). S342G is involved in the predicted binding 
site domain, and is predicted to modify its binding ability. 
: 
 
 
 
  
 
 
Figure 6. Pie charts of allele frequencies for the APOL1 SNP rs73885319 
(S342G) in African Americans and Hispanic Americans cases versus controls. 
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